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Objectives: To assess the cost-effectiveness of the SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg and canagliflozin 
300mg) when administered as an add-on to MET+SU in patients with T2DM in 
the UK. MethOds: Long-term diabetes-related complications, QALYs, and costs 
were estimated for T2DM patients failing MET+SU. A micro-simulation model was 
developed based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model. A network meta-analysis comparing 
efficacy and safety across SGLT2is was used to populate the model. Data gaps were 
completed with information derived from published sources, including previous 
cost-effectiveness models. Costs and QALYs were estimated over a patients’ lifetime 
from the UK National Health Service perspective. Results: Empagliflozin 10mg 
attained the highest QALYs (6.991, compared to 6.98 for canagliflozin 100mg, 6.978 
for empagliflozin 25mg and 6.976 for canagliflozin 300mg) due to slightly better 
HbA1c, SBP and weight control, and a small number of non-severe hypoglycae-
mias, compared to higher doses. Canagliflozin 300mg was the most costly strategy 
(£32,087, vs. £31,217 for canagliflozin 100mg, £31,409 for empagliflozin 10mg and 
£31,557 for empagliflozin 25mg). Therefore, empagliflozin 10mg dominated both 
canagliflozin 300mg and empagliflozin 25mg, and resulted in an incremental cost-
effectiveness ratio of £17,445 per QALY gained vs. canagliflozin 100mg. However, 
incremental QALY and cost differences were not significant based on 95% percentile 
confidence intervals. These results remained robust when sensitivity analyses were 
conducted, including utilities, adverse events, discontinuation, modelling of weight, 
impact of BMI, duration of effect, time horizon and discount rates. cOnclusiOns: 
Differences in QALYs and costs between SGLT2is as add-ons to MET+SU were minor. 
On average, empagliflozin 10mg resulted to be the most cost-effective option for 
T2DM patients failing MET+SU when commonly accepted thresholds in the UK 
were considered, with an incremental cost per QALY of £17,445 compared to cana-
gliflozin 100mg.
PDB111
ABsenteeism AnD Presenteeism in A PoPulAtion of PAtients with 
DiABetic foot ulcers in PolAnD
Zalewska U.1, Macioch T.1, Sobol E.2, Mrozikiewicz-Rakowska B.1, Krakowiecki A.3, 
Hermanowski T.1
1Medical University of Warsaw, Warsaw, Poland, 2Medical University of Warsaw Central Clinical 
Hospital, Warsaw, Poland, 3PODOS, Warsaw, Poland
Objectives: Diabetic Foot Syndrome (DFS) is a serious and common complica-
tion of diabetes, often leading to limb amputation and disability. Disability and 
productivity loss in patients with DFS can generate significant indirect costs and 
potentially significant economic consequences. The purpose of the study is to esti-
mate productivity loss and indirect costs associated with foot ulceration in patients 
with DFS. MethOds: We conducted a prospective survey in a population of DFS 
patients with foot ulceration. Loss of productivity was measured with a modified 
WPAI questionnaire. Indirect costs of both absenteeism and presenteeism were 
estimated using the human capital approach on the basis of the measure of gross 
value added per employee. Results: Nearly one third of respondents (32%) declared 
that foot ulceration was the direct reason why they abandoned their professional 
activity. 40% and 34% of respondents, respectively, were forced to limit or change 
their professional activity at some point in the past because of the foot ulceration. 
More than 40% of respondents who changed or limited their professional activity 
because of the foot ulceration experienced reduction in earnings by 22.9% on aver-
age. Mean absenteeism was estimated at 32.63% of the nominal working time, while 
presenteeism was estimated at 23.48% of real working time. Total annual indirect 
costs associated with productivity loss amounted to EUR 170.8 million, including 
EUR 117.3 million of the costs of sickness absence and EUR 53.5 million of the costs 
of presenteeism. cOnclusiOns: Foot ulceration in patients with DFS is a com-
mon cause why patients are forced to give up or change their professional activity, 
which usually leads to a reduction in earnings. Indirect costs associated with foot 
ulceration in DFS impose a significant burden on the Polish economy. There is no 
rationale that would clearly link productivity loss associated with ulceration in DFS 
and the ulceration severity.
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Objectives: Insulin administration in the acute care setting is an integral com-
ponent of inpatient diabetes management. The current method of administration 
in acute care settings is by vial and syringe. The aim of this study was to evalu-
ate the impact of insulin pen implementation in the acute care setting on patient 
and health care worker safety, and health resource utilization (HRU). MethOds: A 
review of published literature was conducted to identify how insulin pen devices 
in the acute care setting may impact inpatient diabetes management. Additionally, 
nurse researchers from the McGill University Health Centre conducted a pilot study 
in a 52-bed unit to quantify this impact in a local context. Together, the results of 
the literature search and the pilot served as the inputs to an economic model, 
developed in Excel v14. Costs for the volume of insulin dispensed, injection sup-
plies, needlestick injury management, and nursing labour were assessed. Results: 
Previous published studies have revealed that insulin pen devices have the poten-
tial to improve inpatient management through better glycemic control, increased 
adherence and improved self-management education. The combined results from 
the literature and pilot indicate that moving from vial and non-safety syringe to 
a passive safety pen in acute care results in total estimated annual cost savings 
of $43,339.66, and 191.42 hours of nursing time saved (site with 52 beds dedicated 
to patients with diabetes). Cost savings from the adoption of a passive safety 
insulin pen were predicted based on reductions in insulin volume and needle-
stick injuries. For an institution of similar size using safety syringes, the move to a 
the comparative efficacy and safety across SGLT2is. Data gaps were completed with 
information derived from published sources, including previous cost-effectiveness 
analyses. The UK National Health Service (NHS) perspective was considered to esti-
mate costs and QALYs over a patients’ lifetime. Results: There were small differ-
ences in efficacy and safety across SGLT2is, which resulted in minor QALY and cost 
differences across treatment combinations. On average, empagliflozin 25mg obtained 
incremental QALYs of 0.029 versus dapagliflozin 10mg and 0.019 versus canagliflozin 
100mg, and incremental costs of £178 and £86, respectively, whereas both canagli-
flozin 300mg and empagliflozin 10mg were dominated by empagliflozin 25mg. This 
resulted in an incremental cost-effectiveness ratio (ICER) of £4,858 per QALY gained 
with empagliflozin 25mg vs. canagliflozin 100mg. However, the differences across 
treatments were not significant when 95% percentile confidence intervals were 
considered. These results were robust to a number of sensitivity analyses including 
a 10-year time horizon, BMI impact, discount rates and parameter values related 
to utilities, disutilities, adverse events, and discontinuation rates. cOnclusiOns: 
Overall, differences in QALYs and costs were minor between SGLT2is used as add-on 
to metformin in UK T2DM patients. On average, empagliflozin 25mg was the most 
cost-effective strategy, with an ICER of £4,858 per QALY gained vs. canagliflozin 100mg.
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Objectives: A small, minimally-invasive flash glucose monitor (FGM) has recently 
been developed. Arm sensors worn up to 14 days interact with a hand-held reader 
to convey 8 hours of continuous glucose level data. The reader stores data, com-
municating glucose control via trend charts. Economic evaluation of FGM vs. con-
ventional blood glucose monitoring (BGM) has not been conducted. This analysis 
estimates potential cost-effectiveness of using FGM in UK insulin-treated type 2 
diabetes mellitus (T2DM) patients. MethOds: The IMS Core Diabetes Model (CDM) 
was used for analyses, assuming a lifetime horizon (40 years). Patient characteristics 
were based on early FGM feasibility trial data. Effectiveness was measured in life 
years (LY) and quality-adjusted life years (QALY), with assumptions around FGM 
effectiveness based on expected benefits of use. These include: a) lower HbA1c by 
0.35%-0.5% compared to BGM over the horizon; b) utility improvement due to fewer 
finger pricks of 0-0.03; c) minor hypoglycaemic event rate reduction of 0% or 50% 
compared to BGM due to potential improved glycaemic control. Cost data (direct 
costs only) were extracted from published literature and government sources, and 
inflated to 2013 GBP. Incremental cost-effectiveness ratios (ICERs) were estimated, 
and threshold analysis was performed to estimate potential total FGM sensor costs 
for each scenario. Results: Based on assumptions above, the ICER for FGM vs. 
BGM ranges from £10,034-£29,068/QALY. With 0.5% HbA1c improvement, 0.01 util-
ity benefit, and no difference in hypoglycaemic events, the ICER is £17,808/QALY. 
Assumptions around utility improvement have a larger ICER impact than HbA1c 
benefit or change in minor hypoglycaemic events. Threshold analysis shows that 
with a conventional ICER threshold (£30,000/QALY), £14,606-£27,956 can be spent on 
sensors over a lifetime across scenarios. cOnclusiOns: Using an alternate glucose 
monitoring method could be cost-effective across a variety of clinical benefit and 
cost assumptions in T2DM (T1DM analysis forthcoming).
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Objectives: To evaluate the cost-effectiveness of canagliflozin, an active inhibitor 
of sodium glucose co-transporter – 2 (SGLT2), in triple therapy of diabetes as add-
on to metformin and sulfonylurea compared to NPH insulin in combination with 
oral antidiabetics. Canagliflozin in clinical trial results showed effective glucose 
reduction, along with other benefits in diabetes treatment including weight loss 
and SBP reduction. Cost effectiveness analyses were conducted in the Polish set-
ting from a public perspective in accordance with guidelines of Polish HTA Agency 
(PolAHTA). MethOds: The IMS CORE Diabetes Model was used to evaluate the 
cost-effectiveness of canagliflozin in triple therapy versus NPH insulin using Polish-
specific data, where available. Clinical data were derived from mixed treatment 
comparison analysis of published studies, as there is no head to head trial com-
paring canagliflozin with NPH insulin. Direct costs were reported in Polish zloty 
and an annual discount rate of 5% and 3.5% were applied on costs and effects 
respectively. Results: In a triple therapy as add-on to metformin and sulfonylurea 
canagliflozin is a cost- effective treatment option in comparison with NPH insulin 
with ICERs of 4 477 z³ and 69 081 z³ for canagliflozin 100 mg and 300 mg respec-
tively. Associated QALY gains were 0,084 and 0,106. Both results are below defined 
in Polish reimbursement act cost-effectiveness threshold. cOnclusiOns: These 
results suggest that adding Canagliflozin to dual therapy versus insulin intensifica-
tion in patients inadequately controlled with MET+ SU would be a more efficient 
use of health care resources in the Polish setting.
PDB110
cost-effectiveness of emPAgliflozin (JArDiAnce®) 10 mg AnD 25 mg 
ADministereD As An ADD-on to metformin AnD sulfonilureA (met+su) 
comPAreD to other soDium-glucose co-trAnsPorter 2 inhiBitors 
(sglt2is) in PAtients with tyPe 2 DiABetes mellitus (t2Dm) in the uk
Aguiar-Ibáñez R.1, Palencia R.2, Kandaswamy P.3, Li L.1
1Amaris Consulting UK, London, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 
3Boehringer Ingelheim UK, Bracknell, UK
